Arcutis Biotherapeutics (ARQT), announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the safety and tolerability of ARQ-234. The investigational biologic, administered as a subcutaneous injection, is being evaluated in sequential cohorts, with single-ascending-dose cohorts in healthy volunteers and adults with moderate to severe atopic dermatitis, followed by multiple-ascending-dose cohorts and a small proof-of-concept cohort in the adults with atopic dermatitis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target lowered to $35 from $37 at Mizuho
- Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim
- Arcutis Biotherapeutics price target raised to $35 from $30 at TD Cowen
- Arcutis Biotherapeutics price target raised to $35 from $32 at Morgan Stanley
- Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating